Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

[1]  S. Emanuel,et al.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.

[2]  G. Perez,et al.  Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. , 2005, Cancer research.

[3]  P. Atadja,et al.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 , 2005, Molecular Cancer Therapeutics.

[4]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[6]  H. Saya,et al.  RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. , 2005, Cancer research.

[7]  S. Bates,et al.  Inhibitors of Histone Deacetylases Alter Kinetochore Assembly by Disrupting Pericentromeric Heterochromatin , 2005, Cell cycle.

[8]  G. Kao,et al.  Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents , 2005, Cancer biology & therapy.

[9]  Manuel Hidalgo,et al.  Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. , 2005, Cancer research.

[10]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[11]  J. Bradner,et al.  INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS , 2005 .

[12]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[13]  Lucia Altucci,et al.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[14]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[15]  Sang Gyun Kim,et al.  Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation , 2004, Clinical Cancer Research.

[16]  M. Caraglia,et al.  Acetylation of proteins as novel target for antitumor therapy: Review article , 2004, Amino Acids.

[17]  G. Almouzni,et al.  HP1 and the dynamics of heterochromatin maintenance , 2004, Nature Reviews Molecular Cell Biology.

[18]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[19]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. , 2003, Molecular cancer therapeutics.

[20]  P. Atadja,et al.  N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). , 2003, Journal of medicinal chemistry.

[21]  D. Cimini,et al.  Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. , 2003, Molecular biology of the cell.

[22]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[23]  So-jung Kim,et al.  Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation , 2003, Oncogene.

[24]  D. V. Von Hoff,et al.  Targeting Aurora-2 kinase in cancer. , 2003, Molecular cancer therapeutics.

[25]  D. Glover,et al.  Polar expeditions — provisioning the centrosome for mitosis , 2003, Nature Cell Biology.

[26]  A. Cohen.  Surgeons as an Integral Part of the Cancer Research Team , 2003, Cancer biology & therapy.

[27]  Zhen Dou,et al.  Function and regulation of Aurora/Ipl1p kinase family in cell division , 2003, Cell Research.

[28]  S. Horinouchi,et al.  In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.

[29]  T. Fojo,et al.  Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. , 2002, Molecular cancer therapeutics.

[30]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[31]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[32]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[33]  S. Schreiber,et al.  Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. , 2001, Organic letters.

[34]  G. Almouzni,et al.  Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases , 2001, Nature Cell Biology.

[35]  C. Peterson,et al.  Global Role for Chromatin Remodeling Enzymes in Mitotic Gene Expression , 2000, Cell.

[36]  G Brosch,et al.  Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. , 1999, Journal of medicinal chemistry.